Hyderabad-based Dr Reddy’s inks pact with Johnson & Johnson to acquire vertigo treatment brand
Dr Reddy’s Laboratories has acquired the anti-vertigo brand Stugeron from Johnson & Johnson in 18 EMEA and APAC markets, including India and Vietnam. The move strengthens its CNS portfolio and supports its goal to reach 1.5 billion patients by 2030
New Delhi: Dr Reddy’s Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets.
Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. The acquisition presents a strategic opportunity for the Hyderabad-based drug firm to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio, Dr Reddy’s Laboratories said in a statement.
Dr Reddy’s acquisition of the brand reflects a steady advancement in the company’s efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of CNS portfolio, said MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories.
“Backed by our strong market access, we intend to extend the reach of Stugeron and its associated products across 18 key markets in the APAC and EMEA regions, including India and Vietnam,” he added.
This strategic step is in line with the drug firm’s broader commitment to improving patient access and advancing toward the goal of reaching over 1.5 billion patients by 2030, he said.
